Cantargia co-founder to present at International Conference on Chronic Myeloid Leukemia

Lund, Sweden; September 20, 2011– Cantargia AB announced today that the company’s co-founder Professor Thoas Fioretos will present at the International Conference on Chronic Myeloid Leukemia in Estoril, Portugal at 11:05AM local time on September 23, 2011.

About Cantargia AB
Cantargia AB is a research and development company based on the original discovery by Professor Thoas Fioretos and Dr. Marcus Järås at the Lund University. Cantargia is focused on developing a conceptually new therapy for the treatment of hematological malignancies (leukemia) which utilizes the expression of a unique cell-surface receptor on hematopoietic stem cells.

Our primary goal is to improve the lives of patients by developing antibody therapeutics with the potential to eliminate the leukemic stem cells that cause the disease.

For more information on Cantargia visit www.cantargia.com.